ADMA Biologics (NASDAQ:ADMA) Rating Reiterated by HC Wainwright

Share on StockTwits

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Friday, TipRanks reports. They presently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 322.54% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. BidaskClub downgraded ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 29th. Oppenheimer dropped their price objective on shares of ADMA Biologics from $14.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $7.40.

ADMA stock opened at $2.84 on Friday. The business has a 50-day simple moving average of $2.79 and a 200 day simple moving average of $3.56. ADMA Biologics has a 52 week low of $1.45 and a 52 week high of $5.48. The company has a quick ratio of 8.14, a current ratio of 11.90 and a debt-to-equity ratio of 1.02. The company has a market cap of $251.26 million, a PE ratio of -3.23 and a beta of 2.03.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.13). ADMA Biologics had a negative net margin of 151.18% and a negative return on equity of 105.97%. The business had revenue of $10.20 million during the quarter, compared to analyst estimates of $10.71 million. On average, analysts anticipate that ADMA Biologics will post -0.72 EPS for the current fiscal year.

In other ADMA Biologics news, major shareholder Perceptive Advisors Llc bought 500,000 shares of ADMA Biologics stock in a transaction on Thursday, March 19th. The shares were purchased at an average cost of $2.10 per share, with a total value of $1,050,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 15.20% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC lifted its holdings in shares of ADMA Biologics by 44.0% during the first quarter. Perceptive Advisors LLC now owns 16,584,802 shares of the biotechnology company’s stock worth $47,764,000 after purchasing an additional 5,063,700 shares during the period. BlackRock Inc. raised its position in ADMA Biologics by 33.5% during the 1st quarter. BlackRock Inc. now owns 5,300,167 shares of the biotechnology company’s stock worth $15,265,000 after purchasing an additional 1,329,060 shares during the last quarter. Sphera Funds Management LTD. raised its position in ADMA Biologics by 240.4% during the 1st quarter. Sphera Funds Management LTD. now owns 1,838,100 shares of the biotechnology company’s stock worth $5,294,000 after purchasing an additional 1,298,100 shares during the last quarter. Prosight Management LP acquired a new position in ADMA Biologics during the 1st quarter worth about $3,579,000. Finally, State Street Corp grew its position in shares of ADMA Biologics by 41.4% in the 1st quarter. State Street Corp now owns 1,192,476 shares of the biotechnology company’s stock valued at $3,434,000 after buying an additional 349,110 shares during the last quarter. 40.62% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Further Reading: Dividend Achievers

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

TheStreet Lowers Charles & Colvard, Ltd.  to D
TheStreet Lowers Charles & Colvard, Ltd. to D
Consolidated Communications  Lifted to C at TheStreet
Consolidated Communications Lifted to C at TheStreet
Corelogic  Upgraded at TheStreet
Corelogic Upgraded at TheStreet
Chuy’s  Cut to D+ at TheStreet
Chuy’s Cut to D+ at TheStreet
Cato  Downgraded by TheStreet
Cato Downgraded by TheStreet
TheStreet Lowers Agilysys  to D
TheStreet Lowers Agilysys to D


© 2006-2020 Ticker Report